OmniAb, Inc. (OABI)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$4.33-8.84%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · OABI
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | |
|---|---|---|---|---|---|---|---|
| Revenues | |||||||
| Revenues | 38.5 | 18.7 | 26.4 | 34.2 | 59.1 | 34.7 | — |
| Operating Expenses & Income | |||||||
| R&D Expenses | 43.5 | 47.8 | 55.1 | 56.5 | 48.4 | 39.2 | — |
| Other Operating Expenses, Total | (0.2) | 2.5 | 2.4 | (0.2) | 0.6 | (1.2) | — |
| Operating Income | (48.4) | (69.0) | (74.5) | (69.4) | (26.6) | (35.6) | — |
| Earnings from Continuing Operations | |||||||
| Interest Expense | — | — | — | — | 0.0 | 0.0 | — |
| Interest & Investment Income | 2.6 | 2.7 | 3.1 | 5.1 | 0.6 | 0.0 | — |
| Net Interest Expenses | — | — | — | — | (0.6) | 0.0 | — |
| Other Non-Operating Income / Expenses | 2.7 | 2.7 | 3.1 | 5.1 | 0.6 | 1.3 | — |
| EBT, Incl. Unusual Items | (45.7) | (66.3) | (71.4) | (64.4) | (26.1) | (34.4) | — |
| Income Tax Expense | (1.4) | (1.5) | (9.4) | (13.7) | (3.7) | (7.3) | — |
| Net Income | |||||||
| Net Income | (44.3) | (64.8) | (62.0) | (50.6) | (22.3) | (27.0) | — |
| Per Share | |||||||
| Basic EPS | (0.34) | (0.57) | (0.61) | (0.51) | (0.26) | (0.33) | — |
| Diluted EPS | (0.34) | (0.57) | (0.61) | (0.51) | (0.26) | (0.33) | — |
| Revenue per Share | 0.30 | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 128.8 | 113.6 | 102.4 | 99.7 | 85.3 | 82.6 | — |
| Diluted Weighted Avg Shares | 128.8 | 113.6 | 102.4 | 99.7 | 85.3 | 82.6 | — |
| Supplemental | |||||||
| EBITDA | — | (47.2) | (50.9) | (49.9) | (8.4) | (19.4) | — |
| EBIT | (48.4) | (69.0) | (74.5) | (69.4) | (26.6) | (35.6) | — |
| Effective Tax Rate | 3.1% | — | — | 21.4% | 14.3% | 21.3% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.